Pakistan: World’s Largest Contributor to Hepatitis C: Report

Pakistan’s public health infrastructure is facing a systemic crisis as the nation emerges as the global epicenter of Hepatitis C. While the medical community has long known that the virus is curable, a devastating combination of regulatory failure and clandestine medical practices has turned a treatable condition into a national emergency.

The Deep Dive: A Breakdown of the Transmission Cycle

The findings of the WHO Global Hepatitis Report 2026 highlight a grim reality: the prevalence of Hepatitis C in Pakistan is not merely a medical failure, but a regulatory one. The report underscores a dangerous synergy between weak infection prevention and a thriving black market for medical supplies. The discovery of banned reusable syringes and counterfeit auto-disable syringes in the open market suggests a collapse in the supply chain oversight.

In many regions, the vacuum left by insufficient formal healthcare is filled by unqualified practitioners—often referred to as “quacks.” These individuals frequently utilize unnecessary injections and reuse equipment, creating a direct pipeline for blood-borne pathogens. Because Hepatitis B and C can remain asymptomatic for years, many citizens are unaware of their status until they reach the stage of liver failure or cancer, at which point the window for simple curative treatment has narrowed significantly.

On a global scale, the stakes are immense. With 287 million people living with chronic hepatitis B or C as of 2024, the WHO emphasizes that these infections account for over 95% of viral hepatitis-related deaths worldwide. Pakistan’s position as the leading contributor to the HCV burden places a disproportionate strain on its already fragile healthcare system.

The Forward Look: What Happens Next?

The revelation that Pakistan “stands out clearly” in the WHO report will likely trigger an urgent shift in national health policy. We can expect several critical developments in the coming months:

1. Regulatory Crackdowns: There will likely be increased pressure on the Drug Regulatory Authority of Pakistan (DRAP) to purge the market of counterfeit syringes and enforce the ban on reusable medical equipment with harsher penalties for vendors.

2. Scaling the “Cure” Narrative: Since Hepatitis C is curable, the government may be forced to launch more aggressive, subsidized screening and treatment campaigns using Direct-Acting Antivirals (DAAs) to reduce the reservoir of infection.

3. Targetting Unqualified Practitioners: This report provides the necessary evidence for health officials to launch a nationwide crackdown on unlicensed clinics. However, the challenge remains: until formal healthcare is accessible in rural areas, the demand for “quacks” will persist.

The ultimate metric of success will not be the number of people treated, but the ability of the state to secure the medical supply chain. Without ending the cycle of unsafe injections, Pakistan will continue to treat the symptoms of a crisis while the cause remains embedded in its healthcare delivery system.